Get the Stockscreener App
28.84
0.72%
-0.21
After Hours:
28.42
-0.42
-1.46%
10 X Genomics Inc stock is traded at $28.84, with a volume of 2.01M.
It is down -0.72% in the last 24 hours and up +37.86% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$29.05
Open:
$29.49
24h Volume:
2.01M
Relative Volume:
0.74
Market Cap:
$3.66B
Revenue:
$638.78M
Net Income/Loss:
$-22.66M
P/E Ratio:
-165.37
EPS:
-0.1744
Net Cash Flow:
$122.18M
1W Performance:
-7.09%
1M Performance:
+37.86%
6M Performance:
+86.55%
1Y Performance:
+172.59%
1-Day Range:
$28.39
$30.00
1-Week Range:
$28.01
$31.68
52-Week Range:
$10.17
$35.65
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
28.84 | 3.69B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
159.54 | 26.24B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
63.23 | 12.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
47.82 | 8.90B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
88.34 | 7.44B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
65.34 | 5.01B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics buys Proteintech Genomics - MSN
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities - TradingView
10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches (NASDAQ:TXG) - Seeking Alpha
Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge? - Yahoo Finance
10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocus
10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz
Is 10x Genomics' Latest Acquisition a Game-Changer for Proteomics - Kavout
10x Genomics acquires Proteintech Genomics division By Investing.com - Investing.com India
10x Genomics acquires Proteintech Genomics division - Investing.com
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - Barchart
CenterBook Partners LP Invests $3.76 Million in 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) awards 8,829 RSUs to company director - Stock Titan
10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan
10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan
10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan
10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026 - Stock Titan
10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan
10x Genomics Shareholders Reelect Directors, Ratify Auditor - TipRanks
10x Genomics, Inc. acquired Proteintech Genomics from ProteinTech Group Inc. - marketscreener.com
10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com
10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock Titan
TXG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Deutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors. - Yahoo Finance
10X Genomics Hits Day High with 9.72% Surge, Outperforming Market - Markets Mojo
10x Genomics stock hits 52-week high at 26.56 USD By Investing.com - Investing.com Nigeria
10x Genomics stock hits 52-week high at 26.56 USD - Investing.com
10x genomics president Hindson sells $283,399 in company stock By Investing.com - Investing.com Australia
10x genomics president Hindson sells $283,399 in company stock - Investing.com UK
10x genomics CEO Serge Saxonov sells $709,057 in shares - Investing.com
10x Genomics CFO Adam Taich sells $369,017 in stock By Investing.com - Investing.com South Africa
10x Genomics CFO Adam Taich sells $369,017 in stock - Investing.com
10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan
10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock Titan
10x Genomics (TXG) CFO sells 15,098 shares to cover RSU taxes - Stock Titan
TXG - Finviz
TXG Genomics (NASDAQ: TXG) Serge Saxonov lists recent Class A sales in Form 144 - Stock Titan
Citigroup downgrades 10x Genomics (TXG) - MSN
10x Genomics Inc Class A Trade Ideas — LS:A2PPQJ - TradingView
Serge Saxonov (TXG) reports multiple 2026 sales and a 35,270-share RSU grant - Stock Titan
TXG (NASDAQ) Form 144: RSU grant 26,276 shares; insider sold 7,826 - Stock Titan
Adam Taich to sell 32,648 TXG shares (TXG) - Stock Titan
TXG News | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
10x Genomics, Inc.Common Stock (NQ: TXG - FinancialContent
10X Genomics’ SWOT analysis: stock faces profitability test - Investing.com
The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call - Yahoo Finance
10x Genomics Q1 earnings call highlights - MSN
The Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance - Sahm
Precision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG) and Solventum Corporation (SOLV) - The Globe and Mail
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
May 26 '26 |
Sale |
24.71 |
10,718 |
264,833 |
1,138,380 |
| Hindson Benjamin J. | See Remarks |
May 22 '26 |
Sale |
24.44 |
11,595 |
283,399 |
502,000 |
| Taich Adam | Chief Financial Officer |
May 22 '26 |
Sale |
24.44 |
15,098 |
369,018 |
379,898 |
0.10%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):